Synopsis:
Neuland Laboratories jumped sharply after the company reported a staggering rise in export data. It recorded a 433% and 250% growth in exports on a YoY and MoM basis.
The shares of this leading pharma company are in focus after the company posted stellar export highlights during the period. In this article, we will dive more into the details.
With a market capitalization of Rs 20,662 crore, the shares of Neuland Laboratories Ltd made a day high of Rs 16,432 per share, up by 5 percent from its previous day’s closing price of Rs 15,692.55 per share. Over the past five years, the stock has delivered a multibagger return of 1,248 percent against the NIFTY50 return of 120 percent.
As of June 2025, Mukul Agarwal holds a 3.12 percent stake in the company, and Vijay Kedia, through his investment vehicle, Kedia Securities Pvt. Ltd., has a 1.01 percent stake in the business.
About the News
Neuland Laboratories jumped sharply mainly because the company delivered a strong export performance in August 2025. The pharma firm posted exports worth USD 12 million (Rs 106 crore), marking an impressive 433 percent year-on-year jump and a 250 percent month-on-month rise. This sharp growth in overseas sales has boosted investor confidence and pushed the stock to one of its recent highs.
Additionally, the rally is also happening when the reports of pharma exporters’ performances differ. Divi’s Laboratories generated USD 89 million (Rs 783 crore) worth of exports, which is 5 percent higher YoY and 32 percent MoM. Laurus Labs announced a shipment of USD 37.4 million (Rs 329 crore), which is 94 percent higher than last year and 6 percent more than the previous month.
On the other hand, Blue Jet Healthcare’s exports accounted for USD 3.9 million (Rs 34 crore), which is a decrease of USD 8 million compared to a year ago and USD 4.8 million in July 2025, while Syngene International’s exports were USD 7 million (Rs 62 crore) against USD 12 million last year and USD 8 million in July 2025.
Also Read: Stock under ₹100 jumps 5% after receiving ₹58 Cr order for storm water drainage project
Financial Highlights
The company’s revenue for Q1 FY26 came in at Rs 293 crore, down by 33 percent from Rs 440 crore in the same quarter last year. Additionally, on a sequential basis, revenue declined by 11 percent from Rs 328 crore in Q4 FY25.
Coming to its profitability, the company reported a net profit decline of 86 percent to Rs 14 crore in Q1 FY26 as compared to Rs 98 crore in Q1 FY25. Additionally, on a QoQ basis, it recorded a decline of 50 percent from Rs 28 crore.
The company has delivered an ROE and ROCE of 14.83 percent and 18.66 percent respectively, and is currently trading at a high P/E of 156.78x as compared to its industry average of 33.43x.
Neuland Laboratories Limited is the maker and seller of active pharmaceutical ingredients (APIs) in India, Europe, the US, and other countries. Besides that, it offers the services of custom manufacturing and peptide synthesis. Neuland Laboratories Limited, established in 1984, is located in Hyderabad, India.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
